All patients demonstrated marked improvement following hormone replacement therapy and HF management, with symptom resolution within 3–14 days, a mean ejection fraction (EF) increase of 1.75% (range: 0%–3%), and B-type natriuretic peptide (BNP) levels decreasing from an initial range of 518.93–619.13 pg/mL to 108.06–287.63 pg/mL pre-discharge, and further to 20.36–177.24 pg/mL at one-month follow-up. This evidence concerns the gene NPPB and hydrops fetalis.